Fraunhofer Institute for Toxicology and Experimental MedicineGood Laboratory Practice: The Foundation for Internationally Recognized Non-Clinical Safety Data
Change in Management of the GLP Test Facility at Fraunhofer ITEM
As of January 1, 2026, the management of the GLP Test Facility at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM has changed. Prof. Dr. Armin Braun, Head of the Department of Preclinical Pharmacology and Toxicology, has been appointed Head of the GLP Test Facility. He succeeds Prof. Dr. Norbert Krug, Director of Fraunhofer ITEM, who previously held this responsibility. Dr. Sylvia Escher, Head of the Department of Safety Assessment and Toxicology, has been appointed Deputy Head of the GLP Test Facility.
Fraunhofer ITEM is one of the few research institutions in Germany authorized to conduct non-clinical safety studies in compliance with the internationally recognized quality standard of Good Laboratory Practice (GLP). As an officially recognized GLP test facility, the institute meets the highest requirements for data quality, traceability, and integrity, providing industrial and public research partners with the quality standards required for regulatory submissions.
GLP is a central component of the quality assurance systems established at Fraunhofer ITEM, which also include Good Clinical Practice (GCP). Together, these systems support the institute’s translational approach, covering the full spectrum from non-clinical investigations to early clinical development.
Compliance with GLP principles at Fraunhofer ITEM is continuously monitored through study- and facility-based inspections and audits across the toxicology, safety pharmacology, and analytical departments. The responsible monitoring authority has confirmed the institute’s GLP compliance for over three decades. Most recently, the integrity of GLP studies conducted at Fraunhofer ITEM was reaffirmed during the inspection in January 2024.
With this change in management of the GLP test facility, Fraunhofer ITEM continues to further develop and uphold its high-quality standards in non-clinical safety assessment.
